title: Serum survivin increases in prolactinoma.
abstract: BACKGROUND
  Prolactinoma is the most common adult pituitary adenoma. Survivin is a member of the family of inhibitors of apoptosis proteins. Its expression is observed in many tumors. Survivin expression has shown in prolactinoma tissue before but no study exists showing serum survivin level. The aim of the present study was to investigate serum survivin levels in patients with prolactinoma and demonstrate its value in diagnosis of the disease.
  
  
  METHODS
  The group of patients consisted of 25 women, aged from 17 to 51 years. As a control group, 21 healthy women, aged from 22 to 45 years were included. Twenty patients had microprolactinoma, while five patients had macroprolactinoma. All patients had received dopamine agonist treatment. Serum survivin levels were measured in all of the groups.
  
  
  RESULTS
  Survivin levels were significantly higher in prolactinoma patients compared to controls (19.04 (10 - 38) pg/mL; 15.05 (8 - 22) pg/mL; P = 0.042). There was no difference between microadenoma and macroadenoma patients in survivin levels (19.22 (10 - 38) pg/mL; 18.40 (16 - 22) pg/mL; P = 0.914). In correlation analysis, survivin was not correlated with other parameters.
  
  
  CONCLUSIONS
  We consider that higher survivin levels might be a molecular marker predicting the presence of prolactinoma and may be useful for the diagnosis. But large-scale research is needed to clarify its role in diagnosis of prolactinoma patients.
authors.affiliation: Department of Endocrinology, Ankara Training and Research Hospital, Ankara, Turkey.
authors.forename: Fatma Dilek
authors.initials: FD
authors.lastname: Dellal
authors.affiliation: Department of Endocrinology, Istanbul Training and Research Hospital, Istanbul, Turkey.
authors.forename: Mutlu
authors.initials: M
authors.lastname: Niyazoglu
authors.affiliation: Department of Endocrinology, Ankara Training and Research Hospital, Ankara, Turkey.
authors.forename: Suheyla
authors.initials: S
authors.lastname: Gorar
authors.affiliation: Department of Endocrinology, Ankara Training and Research Hospital, Ankara, Turkey.
authors.forename: Esranur
authors.initials: E
authors.lastname: Ademoglu
authors.affiliation: Department of Endocrinology, Ankara Training and Research Hospital, Ankara, Turkey.
authors.forename: Zehra
authors.initials: Z
authors.lastname: Candan
authors.affiliation: Department of Endocrinology, Ankara Training and Research Hospital, Ankara, Turkey.
authors.forename: Handan
authors.initials: H
authors.lastname: Bekdemir
authors.affiliation: Department of Family Medicine, Istanbul Training and Research Hospital, Istanbul, Turkey.
authors.forename: Yalcin
authors.initials: Y
authors.lastname: Hacioglu
authors.affiliation: Department of Internal Medicine, Istanbul Training and Research Hospital, Istanbul, Turkey.
authors.forename: Fatih Oner
authors.initials: FO
authors.lastname: Kaya
keywords: Macroprolactinoma; Microprolactinoma; Pituitary neoplasms; Prolactinoma; Survivin